Market research
CLDX Celldex Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 58.0667
- Dividend yield
- Not available
- Beta
- 0.84
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US15117B2025
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 58.0667
- Dividend yield
- Not available
- Beta
- 0.84
About
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CLDX discussion.
5 years, 4 months ago
Celldex Therapeutics, Inc is currently in a long term uptrend where the price is trading 36.7% above its 200 day moving average.
From a valuation standpoint, the stock is 93.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 89.5.
Celldex Therapeutics, Inc's total revenue sank by 99.2% to $7K since the same quarter in the previous year.
Its net income has increased by 100.0% to $-60 since the same quarter in the previous year.
Finally, its free cash flow grew by 50.9% to $-5M since the same quarter in the previous year.
Based on the above factors, Celldex Therapeutics, Inc gets an overall score of 4/5.